Ivermectin reduces in vivo coronavirus infection in a mouse experimental model

Abstract The objective of this study was to test the effectiveness of ivermectin for the treatment of mouse hepatitis virus (MHV), a type 2 family RNA coronavirus similar to SARS-CoV-2. Female BALB/cJ mice were infected with 6,000 PFU of MHV-A59 (group infected, n = 20) or infected and then immediat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. P. Arévalo, R. Pagotto, J. L. Pórfido, H. Daghero, M. Segovia, K. Yamasaki, B. Varela, M. Hill, J. M. Verdes, M. Duhalde Vega, M. Bollati-Fogolín, M. Crispo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/164acd5bb54b4f4bbec1cff945980aed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:164acd5bb54b4f4bbec1cff945980aed
record_format	dspace
spelling	oai:doaj.org-article:164acd5bb54b4f4bbec1cff945980aed2021-12-02T14:25:16ZIvermectin reduces in vivo coronavirus infection in a mouse experimental model10.1038/s41598-021-86679-02045-2322https://doaj.org/article/164acd5bb54b4f4bbec1cff945980aed2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86679-0https://doaj.org/toc/2045-2322Abstract The objective of this study was to test the effectiveness of ivermectin for the treatment of mouse hepatitis virus (MHV), a type 2 family RNA coronavirus similar to SARS-CoV-2. Female BALB/cJ mice were infected with 6,000 PFU of MHV-A59 (group infected, n = 20) or infected and then immediately treated with a single dose of 500 µg/kg ivermectin (group infected + IVM, n = 20) or were not infected and treated with PBS (control group, n = 16). Five days after infection/treatment, the mice were euthanized and the tissues were sampled to assess their general health status and infection levels. Overall, the results demonstrated that viral infection induced typical MHV-caused disease, with the livers showing severe hepatocellular necrosis surrounded by a severe lymphoplasmacytic inflammatory infiltration associated with a high hepatic viral load (52,158 AU), while mice treated with ivermectin showed a better health status with a lower viral load (23,192 AU; p < 0.05), with only a few having histopathological liver damage (p < 0.05). No significant differences were found between the group infected + IVM and control group mice (P = NS). Furthermore, serum transaminase levels (aspartate aminotransferase and alanine aminotransferase) were significantly lower in the treated mice than in the infected animals. In conclusion, ivermectin diminished the MHV viral load and disease in the mice, being a useful model for further understanding this therapy against coronavirus diseases.A. P. ArévaloR. PagottoJ. L. PórfidoH. DagheroM. SegoviaK. YamasakiB. VarelaM. HillJ. M. VerdesM. Duhalde VegaM. Bollati-FogolínM. CrispoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q A. P. Arévalo R. Pagotto J. L. Pórfido H. Daghero M. Segovia K. Yamasaki B. Varela M. Hill J. M. Verdes M. Duhalde Vega M. Bollati-Fogolín M. Crispo Ivermectin reduces in vivo coronavirus infection in a mouse experimental model
description	Abstract The objective of this study was to test the effectiveness of ivermectin for the treatment of mouse hepatitis virus (MHV), a type 2 family RNA coronavirus similar to SARS-CoV-2. Female BALB/cJ mice were infected with 6,000 PFU of MHV-A59 (group infected, n = 20) or infected and then immediately treated with a single dose of 500 µg/kg ivermectin (group infected + IVM, n = 20) or were not infected and treated with PBS (control group, n = 16). Five days after infection/treatment, the mice were euthanized and the tissues were sampled to assess their general health status and infection levels. Overall, the results demonstrated that viral infection induced typical MHV-caused disease, with the livers showing severe hepatocellular necrosis surrounded by a severe lymphoplasmacytic inflammatory infiltration associated with a high hepatic viral load (52,158 AU), while mice treated with ivermectin showed a better health status with a lower viral load (23,192 AU; p < 0.05), with only a few having histopathological liver damage (p < 0.05). No significant differences were found between the group infected + IVM and control group mice (P = NS). Furthermore, serum transaminase levels (aspartate aminotransferase and alanine aminotransferase) were significantly lower in the treated mice than in the infected animals. In conclusion, ivermectin diminished the MHV viral load and disease in the mice, being a useful model for further understanding this therapy against coronavirus diseases.
format	article
author	A. P. Arévalo R. Pagotto J. L. Pórfido H. Daghero M. Segovia K. Yamasaki B. Varela M. Hill J. M. Verdes M. Duhalde Vega M. Bollati-Fogolín M. Crispo
author_facet	A. P. Arévalo R. Pagotto J. L. Pórfido H. Daghero M. Segovia K. Yamasaki B. Varela M. Hill J. M. Verdes M. Duhalde Vega M. Bollati-Fogolín M. Crispo
author_sort	A. P. Arévalo
title	Ivermectin reduces in vivo coronavirus infection in a mouse experimental model
title_short	Ivermectin reduces in vivo coronavirus infection in a mouse experimental model
title_full	Ivermectin reduces in vivo coronavirus infection in a mouse experimental model
title_fullStr	Ivermectin reduces in vivo coronavirus infection in a mouse experimental model
title_full_unstemmed	Ivermectin reduces in vivo coronavirus infection in a mouse experimental model
title_sort	ivermectin reduces in vivo coronavirus infection in a mouse experimental model
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/164acd5bb54b4f4bbec1cff945980aed
work_keys_str_mv	AT aparevalo ivermectinreducesinvivocoronavirusinfectioninamouseexperimentalmodel AT rpagotto ivermectinreducesinvivocoronavirusinfectioninamouseexperimentalmodel AT jlporfido ivermectinreducesinvivocoronavirusinfectioninamouseexperimentalmodel AT hdaghero ivermectinreducesinvivocoronavirusinfectioninamouseexperimentalmodel AT msegovia ivermectinreducesinvivocoronavirusinfectioninamouseexperimentalmodel AT kyamasaki ivermectinreducesinvivocoronavirusinfectioninamouseexperimentalmodel AT bvarela ivermectinreducesinvivocoronavirusinfectioninamouseexperimentalmodel AT mhill ivermectinreducesinvivocoronavirusinfectioninamouseexperimentalmodel AT jmverdes ivermectinreducesinvivocoronavirusinfectioninamouseexperimentalmodel AT mduhaldevega ivermectinreducesinvivocoronavirusinfectioninamouseexperimentalmodel AT mbollatifogolin ivermectinreducesinvivocoronavirusinfectioninamouseexperimentalmodel AT mcrispo ivermectinreducesinvivocoronavirusinfectioninamouseexperimentalmodel
_version_	1718391354644496384

Ivermectin reduces in vivo coronavirus infection in a mouse experimental model

Ejemplares similares